- Home
- CMPS vs ATXS Comparison
CMPS vs ATXS Comparison
Compare CMPS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- ATXS
- Stock Information
- Founded
- CMPS 2020
- ATXS 2008
- Country
- CMPS United Kingdom
- ATXS United States
- Employees
- CMPS N/A
- ATXS N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- ATXS Health Care
- Exchange
- CMPS Nasdaq
- ATXS Nasdaq
- Market Cap
- CMPS 364.9M
- ATXS 401.2M
- IPO Year
- CMPS 2020
- ATXS 2015
- Fundamental
- Price
- CMPS $4.33
- ATXS $6.70
- Analyst Decision
- CMPS Strong Buy
- ATXS Strong Buy
- Analyst Count
- CMPS 7
- ATXS 7
- Target Price
- CMPS $17.83
- ATXS $32.43
- AVG Volume (30 Days)
- CMPS 2.3M
- ATXS 240.5K
- Earning Date
- CMPS 07-31-2025
- ATXS 08-11-2025
- Dividend Yield
- CMPS N/A
- ATXS N/A
- EPS Growth
- CMPS N/A
- ATXS N/A
- EPS
- CMPS N/A
- ATXS N/A
- Revenue
- CMPS N/A
- ATXS N/A
- Revenue This Year
- CMPS N/A
- ATXS N/A
- Revenue Next Year
- CMPS N/A
- ATXS N/A
- P/E Ratio
- CMPS N/A
- ATXS N/A
- Revenue Growth
- CMPS N/A
- ATXS N/A
- 52 Week Low
- CMPS $2.25
- ATXS $3.56
- 52 Week High
- CMPS $8.54
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- CMPS 54.36
- ATXS 65.22
- Support Level
- CMPS $3.92
- ATXS $6.31
- Resistance Level
- CMPS $4.78
- ATXS $7.34
- Average True Range (ATR)
- CMPS 0.35
- ATXS 0.36
- MACD
- CMPS 0.02
- ATXS 0.01
- Stochastic Oscillator
- CMPS 57.81
- ATXS 70.00
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.